The incidence of recurrent venous thromboembolism and chronic thromboembolic pulmonary hypertension following a first episode of pulmonary embolism

Current Opinion in Pulmonary Medicine

Volumn 17, Issue 5, 2011, Pages 392-397

  Poli, Daniela ^a   Miniati, Massimo ^b  

^a Universitaria di Careggi ^*  (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Chronic thromboembolic pulmonary hypertension; D dimer; fibrin; pulmonary embolism; venous thromboembolism recurrence

Indexed keywords

ANTICOAGULANT AGENT; D DIMER; FIBRIN;

ANTICOAGULATION; BLEEDING; CHRONIC DISEASE; CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION; CLINICAL ASSESSMENT; ECHOCARDIOGRAPHY; ENDARTERECTOMY; FIBRIN CLOT; FIBRINOLYSIS; HUMAN; INCIDENCE; INTERNATIONAL NORMALIZED RATIO; LUNG EMBOLISM; MORTALITY; PATHOPHYSIOLOGY; PULMONARY HYPERTENSION; RECURRENCE RISK; RECURRENT DISEASE; REVIEW; RISK FACTOR; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; HUMANS; HYPERTENSION, PULMONARY; INCIDENCE; PULMONARY EMBOLISM; RECURRENCE; RISK FACTORS; VENOUS THROMBOEMBOLISM;

EID: 80051798591     PISSN: 10705287     EISSN: 15316971     Source Type: Journal    
DOI: 10.1097/MCP.0b013e328349289a     Document Type: Review

References (50)

1. Anderson FA Jr, Wheeler HB, Goldberg RJ, et al. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study. Arch Intern Med 1991;151:933-938.
2. Silverstein MD, Heit JA, Mohr DN, et al. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med 1998;158:585-593. (Pubitemid 28144815)
3. Cushman M, Tsai AW, White RH, et al. Deep vein thrombosis and pulmonary embolism in two cohorts: the longitudinal investigation of thromboembolism etiology. Am J Med 2004;117:19-25. (Pubitemid 38801482)
4. Levine MN, Hirsh J, Gent M, et al. Optimal duration of oral anticoagulant therapy: a randomized trial comparing four weeks with three months of warfarin in patients with proximal deep vein thrombosis. Thromb Haemost 1995;74:606-611.
5. Optimum duration of anticoagulation for deep-vein thrombosis and pulmonary embolism. Lancet 1992;340:873-876.
6. Schulman S, Rhedin A-S, Lindmarker P, et al., and the Duration of Anticoagulation Trial Study Group. A comparison of six weeks with six months of oral anticoagulant therapy after the first episode of venous thromboembolism. N Engl J Med 1995;332:1661-1665.
7. Prandoni P, Lensing AWA, Cogo A, et al. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med 1996;125:1-7.
8. Pini M, Aiello S, Manotti C, et al. Low molecular weight heparin versus warfarin in the prevention of recurrence after deep vein thrombosis. Thromb Haemost 1994;72:191-197. (Pubitemid 24251278)
9. Heit JA, Mohr DN, Silverstein MD, et al. Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study. Arch Intern Med 2000;160:761-768. (Pubitemid 30165236)
10. Iorio A, Kearon C, Filippucci E, et al. Risk of recurrence after a first episode of symptomatic venous thromboembolism provoked by a transient risk factor: a systematic review. Arch Intern Med 2010;170:1710-1716. In this analysis, annualized recurrence rates of VTE were calculated and pooled across studies. The risk of recurrence is low if VTE is provoked by surgery, intermediate if provoked by a nonsurgical risk factor, and high if unprovoked.
11. Baglin T, Douketis J, Tosetto A, et al. Does the clinical presentation and extent of venous thrombosis predict likelihood and type of recurrence? A patientlevel meta-analysis. J Thromb Haemost 2010;8:2436-2442. The study reported that, while DVT and pulmonary embolism are manifestations of the same disease, patients presenting with pulmonary embolism are three times more likely to suffer recurrence as pulmonary embolism than patients presenting with DVT. Patients presenting with calf DVT are at low risk of recurrence and at low risk of recurrence as pulmonary embolism.
12. Prandoni P, Lensing AWA, Piccioli A, et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 2002;100:3484-3488. (Pubitemid 35303914)
13. Kearon C, Kahn SR, Agnelli G, et al., American College of Chest Physicians. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008;133:454S-545S. (Pubitemid 351892971)
14. Baglin T, Luddington R, Brown K, et al. Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: prospective cohort study. Lancet 2003;362:523-526. (Pubitemid 36976716)
15. Christiansen SC, Cannegieter SC, Koster T, et al. Thrombophilia, clinical factors, and recurrent venous thrombotic events. JAMA 2005;293:2352-2361. (Pubitemid 40676757)
16. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006;4:295-330.
17. Douketis J, Tosetto A, Marcucci M, et al. Risk of recurrence after venous thromboembolism in men and women: patient level meta-analysis. BMJ 2011;342:d813. doi:10.1136/bmj.d813. The results of this large patient level meta-analysis reported that in patients with a first unprovoked venous thromboembolism, men have a 2.2-fold higher risk of recurrent venous thromboembolism than do women, which remained 1.8-fold higher in men after adjustment for previous hormone associated venous thromboembolism.
18. Palareti G, Legnani C, Cosmi B, et al. Risk of venous thromboembolism recurrence: high negative predictive value of D-dimer performed after oral anticoagulation is stopped. Thromb Haemost 2002;87:7-12. (Pubitemid 34092568)
19. Verhovsek M, Douketis JD, Yi Q, et al. Systematic review: D-dimer to predict recurrent disease after stopping anticoagulant therapy for unprovoked venous thromboembolism. Ann Intern Med 2008;149:481-490.
20. Pengo V, Palareti G, Cosmi B, et al. D-dimer testing and recurrent venous thromboembolism after unprovoked pulmonary embolism: A posthoc analysis of the prolong extension study. Thromb Haemost 2008;100:718-721.
21. Schulman S. Quality of oral anticoagulant control and treatment in Sweden. Duration of Anticoagulation (DURAC) Trial Study Group. J Intern Med 1994;236:143-152. (Pubitemid 24246970)
22. Palareti G, Cosmi B, Legnani C, et al. D-dimer testing to determine the duration of anticoagulation therapy. N Engl J Med 2006;355:1780-1789. (Pubitemid 44631361)
23. Fanikos J, Correnti GN, Shah R, et al. Major bleeding complications in a specialized anticoagulation service. Am J Cardiol 2005;96:595-598. (Pubitemid 41132782)
24. Linkins LA, Choi PT, Douketis JD. Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism: a metaanalysis. Ann Intern Med 2003;139:893-900.
25. Agnelli G, Prandoni P, Becattini C, et al. Extended oral anticoagulant therapy after a first episode of pulmonary embolism. Ann Intern Med 2003;139:19-25.
26. Auger WR, Kim NH, Kerr KM, et al. Chronic thromboembolic pulmonary hypertension. Clin Chest Med 2007;28:255-269. (Pubitemid 46330546)
27. Dalen JE, Alpert JS. Natural history of pulmonary embolism. Prog Cardiovasc Dis 1975;18:696-702.
28. Fedullo PF, Auger WR, Kerr KM, et al. Chronic thromboembolic pulmonary hypertension. N Engl J Med 2001;345:1465-1472.
29. Ribeiro A, Lindmarker PL, Johnsson H, et al. Pulmonary embolism: one-year follow-up with echocardiography Doppler and five-year survival analysis. Circulation 1999;99:1325-1330. (Pubitemid 29129917)
30. Pengo V, Lensing AW, Prins MH, et al., for the Thromboembolic Pulmonary Hypertension Study Group. Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N Engl J Med 2004;350:2257-2264.
31. Miniati M, Monti S, Bottai M, et al. Survival and restoration of pulmonary perfusion in a long-term follow-up of patients after acute pulmonary embolism. Medicine (Baltimore) 2006;85:253-262. (Pubitemid 44401458)
32. Becattini C, Agnelli C, Pesavento R, et al. Incidence of chronic thromboembolic pulmonary hypertension after a first episode of pulmonary embolism. Chest 2006;130:172-175. (Pubitemid 44116856)
33. Poli D, Grifoni E, Antonucci E, et al. Incidence of recurrent venous throm-boembolism and of chronic thromboembolic pulmonary hypertension after a first episode of pulmonary embolism. J Thromb Thrombolysis 2010;30:294-299. The study reported an incidence of CTEPH of 0.4% after a first episode of pulmonary embolism. VTE recurrence and markers of clotting activation such as D-dimer levels were not related to the development of CTEPH.
34. Klok FA, Zondag W, van Kralingen KW, et al. Patient outcomes after acute pulmonary embolism. A pooled survival analysis of different adverse events. Am J Respir Crit Care Med 2010;181:501-506. The study found that the clinical course of acute pulmonary embolism is complicated by high rates of serious adverse events. Only 70% of patients were without events after 1 year and fewer than 50% after 4 years from the pulmonary embolism. Control patients without pulmonary embolism had significantly better prognosis.
35. Galie N, Kim NHS. Pulmonary microvascular disease in chronic thromboembolic pulmonary hypertension. Proc Am Thorac Soc 2006;3:571-576. (Pubitemid 44411622)
36. Wolf M, Boyer-Neumann C, Parent F, et al. Thrombotic risk factors in pulmonary hypertension. Eur Respir J 2000;15:395-399. (Pubitemid 30085971)
37. Bonderman D, Turecek PL, Jakowitsch J, et al. High prevalence of elevated clotting factor VIII in chronic thromboembolic pulmonary hypertension. Thromb Haemost 2003;90:372-376. (Pubitemid 37138760)
38. Morris TA, Marsh JJ, Chiles PG, et al. Fibrin derived from patients with chronic thromboembolic pulmonary hypertension is resistant to lysis. Am J Respir Crit Care Med 2006;173:1270-1275. (Pubitemid 43848399)
39. Miniati M, Fiorillo C, Becatti M, et al. Fibrin resistance to lysis in patients with pulmonary hypertension other than thromboembolic. Am J Respir Crit Care Med 2010;181:992-996. Fibrin isolated from patients with cCTEPH is resistant to lysis. The study found that fibrin resistance to lysis is not limited to CTEPH as it also occurs in idiopathic and some forms of acquired pulmonary hypertension. Minor resistance of fibrin to lysis was observed in patients with prior pulmonary embolism and no evidence of pulmonary hypertension.
40. Hamaguchi M, Bunce LA, Sporn LA, Francis CW. Spreading of platelets on fibrin is mediated by the amino terminus of the beta chain including peptide beta. Blood 1993;81:2248-2256.
41. Bunce LA, Sporn LA, Francis CW. Cell proliferation on fibrin: modulation by fibrinopeptide cleavage. Blood 1995;86:1802-1810.
42. Lang IM. Chronic thromboembolic pulmonary hypertension: not so rare after all. N Engl J Med 2004;350:2236-2238. (Pubitemid 38669205)
43. Fleischner FG. Pulmonary embolism. Can Med Assoc J 1958;78:653-660.
44. Bajc M, Neilly B, Miniati M, et al. EANM guidelines for ventilation/perfusion scintigraphy. Part1: Pulmonary imaging with ventilation/perfusion single photon emission tomography. Eur J Nucl Med Mol Imaging 2009;36:1356-1370.
45. Bajc M, Neilly B, Miniati M, et al. EANM guidelines for ventilation/perfusion scintigraphy. Part 2: Algorithms and clinical considerations for diagnosis of pulmonary embolism with V/P (SPECT) and MDCT. Eur J Nucl Med Mol Imaging 2009;36:1528-1538.
46. Arcasoy SM, Christie JD, Ferrari VA, et al. Echocardiographic assessment of pulmonary hypertension in patients with advanced lung disease. Am J Respir Crit Care Med 2003;167:735-740. (Pubitemid 36801751)
47. Fisher MR, Forfia PR, Chamera E, et al. Accuracy of Doppler echocardiography in the hemodynamic assessment of pulmonary hypertension. Am J Respir Crit Care Med 2009;179:615-621.
48. The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J 2009;30:2493-2537.
49. Skoro-Sajer N, Hack N, Sadushi-Koliçi R, et al. Pulmonary vascular reactivity and prognosis in patients with chronic thromboembolic pulmonary hypertension: a pilot study. Circulation 2009;119:298-305.
50. Jaïs X, D'Armini AM, Jansa P, et al. Bosentan effects in inoperable forms of chronic thromboembolic pulmonary hypertension study group (BENEFiT): a randomised, placebo-controlled trial. J Am Coll Cardiol 2008;52:2127-2134.